Treatment of peptic ulcers--acid reduction or cytoprotection?
In a Swedish multicenter double blind trial cimetidine was compared to sucralfate in the treatment of peptic ulcer. Patients with endoscopically verified gastric, prepyloric and duodenal ulcers were treated with cimetidine 400 mg x 2 or sucralfate 1 g x 4 for four to eight weeks. Gastric ulcers were treated up to 12 weeks. Patients with healed ulcers were followed for up to 12 months. During follow-up without any anti ulcer treatment control endoscopy was performed 2-4 and 9-11 months after endoscopic healing and at symptomatic recurrence. 647 patients were studied (334 cimetidine and 313 sucralfate). 258 patients were included in the 12 months' follow up: of these 143 were previously treated with cimetidine and 115 with sucralfate. Healing rates were 92% in patients treated with cimetidine and 87% in those given sucralfate (ns). Symptomatic relief and ulcer recurrence did not differ between the treatments. Smoking significantly increased recurrence rate and shortened the time to recurrence in the cimetidine treated patients, but not in the sucralfate group. Cimetidine and sucralfate compared well in all aspects of acute peptic ulcer treatment and recurrence during one year of follow up.
Glise
H
H
Department of surgery; Skovde Torsby, Sweden.
Carling
L
L
Hallerbäck
B
B
Kagevi
I
I
Solhaug
J H
JH
Svedberg
L E
LE
Wahlby
L
L
D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*; D011897:Random Allocation; D012008:Recurrence; D012907:Smoking / Q000009:adverse effects; D013392:Sucralfate / Q000627:therapeutic use*; D013997:Time Factors; D014945:Wound Healing
D013392:Sucralfate; D002927:Cimetidine